ABBV - IGM Biosciences: Early Stage Of Development But With Janus Inside
Sophisticated pharma investors will need to review the IGM Biosciences (IGMS)' preclinical data. Janus Capital Management acquired shares, and the company holds a significant amount of cash. It means that preclinical research impressed institutional investors and may impress others. Having said that, IGM Biosciences is still at an early stage of development, which some participants will dislike. With this in mind, we believe that the enterprise value could fluctuate from $50 million to $250 million.
Source: S-1
Source: S-1
Platform And IGM's Product Candidates
Founded in 2010, IGM Biosciences is a biotechnology company